Investing on the edge
Back to Top

Engineered Biology

Our core biotech investment thesis at Gravity Fund is that humanity’s ability to engineer biology will fundamentally transform how we diagnose, treat, and manage disease. Tools like computational biology, protein folding modeling, evolutionary biology engines, rationally designed nanomaterials, and CRISPR enable an expanding pool of entrepreneurs to simulate, analyze and engineer biology

I’m thrilled to announce the launch of Gravity Fund, a thesis driven early-stage Venture Capital firm, alongside my Co-Founder and Managing Partner, Adam Gruver. We’ll be investing in extraordinary entrepreneurs building bleeding edge technology on the brink of commercialization in four defined sectors: Consumer Marketplaces & Applications, Fintech & Crypto, Enterprise Software,

  Yesterday Google DeepMind announced that their deep learning system AlphaFold has achieved unprecedented levels of accuracy on the “protein folding problem”, a grand challenge problem in computational biochemistry. The ability to accurately predict protein structures from their amino-acid sequence represents a huge boon to life sciences and medicine. It potentially vastly accelerates efforts

  What if you could bring the best version of yourself to everything you do everyday? What if you could untap more of your brain’s potential — or more scientifically, its “cognitive performance”. There are numerous startups asking these very questions. They use a range of methods, including nootropics, gamified brain training, app-led meditation, acoustics, non-invasive